AU2022326575A1 - Engineered high fidelity omni-50 nuclease variants - Google Patents

Engineered high fidelity omni-50 nuclease variants Download PDF

Info

Publication number
AU2022326575A1
AU2022326575A1 AU2022326575A AU2022326575A AU2022326575A1 AU 2022326575 A1 AU2022326575 A1 AU 2022326575A1 AU 2022326575 A AU2022326575 A AU 2022326575A AU 2022326575 A AU2022326575 A AU 2022326575A AU 2022326575 A1 AU2022326575 A1 AU 2022326575A1
Authority
AU
Australia
Prior art keywords
omni
amino acid
nuclease
variant
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022326575A
Other languages
English (en)
Inventor
Rafi EMMANUEL
Asael Herman
Lior IZHAR
Liat ROCKAH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emendobio Inc
Original Assignee
Emendobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emendobio Inc filed Critical Emendobio Inc
Publication of AU2022326575A1 publication Critical patent/AU2022326575A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022326575A 2021-08-12 2022-08-12 Engineered high fidelity omni-50 nuclease variants Pending AU2022326575A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163232571P 2021-08-12 2021-08-12
US63/232,571 2021-08-12
US202263332214P 2022-04-18 2022-04-18
US63/332,214 2022-04-18
US202263333037P 2022-04-20 2022-04-20
US63/333,037 2022-04-20
PCT/US2022/074930 WO2023019263A1 (en) 2021-08-12 2022-08-12 Engineered high fidelity omni-50 nuclease variants

Publications (1)

Publication Number Publication Date
AU2022326575A1 true AU2022326575A1 (en) 2024-03-14

Family

ID=85201002

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022326575A Pending AU2022326575A1 (en) 2021-08-12 2022-08-12 Engineered high fidelity omni-50 nuclease variants

Country Status (8)

Country Link
US (1) US20250283115A1 (https=)
EP (1) EP4384609A4 (https=)
JP (1) JP2024531217A (https=)
KR (1) KR20240043792A (https=)
AU (1) AU2022326575A1 (https=)
CA (1) CA3228366A1 (https=)
IL (1) IL310730A (https=)
WO (1) WO2023019263A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12091688B2 (en) 2021-02-08 2024-09-17 Emendobio Inc. OMNI-103 CRISPR nuclease
KR20230142740A (ko) 2021-02-08 2023-10-11 에멘도바이오 인코포레이티드 Omni-103 crispr 뉴클레아제
CN119546757A (zh) 2022-05-25 2025-02-28 宏基因组学公司 肝酶表达的补充
US20260021141A1 (en) * 2022-07-15 2026-01-22 Emendobio Inc. Strategies For Knock-Ins At APLP2 Safe Harbor Sites
WO2025117858A1 (en) * 2023-11-28 2025-06-05 Metagenomi, Inc. Supplementation of liver enzyme expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512446B1 (en) * 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2020223514A2 (en) * 2019-04-30 2020-11-05 Emendobio Inc. Novel omni-50 crispr nuclease
WO2020223553A2 (en) * 2019-04-30 2020-11-05 Emendobio Inc. Novel omni crispr nucleases
US12435334B2 (en) * 2019-11-06 2025-10-07 Emendobio Inc. Differential knockout of an allele of a heterozygous ELANE gene-II
WO2024168159A1 (en) * 2023-02-08 2024-08-15 Emendobio Inc. Engineered omni-50 nuclease variants

Also Published As

Publication number Publication date
KR20240043792A (ko) 2024-04-03
JP2024531217A (ja) 2024-08-29
IL310730A (en) 2024-04-01
WO2023019263A1 (en) 2023-02-16
EP4384609A1 (en) 2024-06-19
CA3228366A1 (en) 2023-02-16
EP4384609A4 (en) 2025-07-02
US20250283115A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
JP2024050582A (ja) 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ
AU2022326575A1 (en) Engineered high fidelity omni-50 nuclease variants
WO2020223553A9 (en) Novel omni crispr nucleases
WO2021248016A2 (en) Novel omni-59, 61, 67, 76, 79, 80, 81, and 82 crispr nucleases
KR20240135610A (ko) Omni-103 crispr 뉴클레아제-rna 복합체
WO2022226215A1 (en) NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 CRISPR NUCLEASES
EP4441210A2 (en) Engineered high activity omni-79 nuclease variants
AU2022390902A1 (en) Novel omni crispr nucleases
JP2024532784A (ja) 新規なｏｍｎｉ－１１５、１２４、１２７、１４４～１４９、１５９、２１８、２３７、２４８、２５１～２５３及び２５９ｃｒｉｓｐｒヌクレアーゼ
WO2024168159A1 (en) Engineered omni-50 nuclease variants
US20230212562A1 (en) Differential knockout of a heterozygous allele of samd9l
CN118176295A (zh) 工程化高保真度omni-50核酸酶变体
WO2020176463A1 (en) Differential knockout of a heterozygous allele of stat1
HK40112369A (zh) 工程化高保真度omni-50核酸酶变体
WO2024148061A2 (en) Omni xl 1-22 crispr nucleases
WO2021243218A2 (en) Differential knockout of a heterozygous allele of samd9